Alpha Family Trust Purchases Shares of 9,330 Bristol-Myers Squibb (NYSE:BMY)

Alpha Family Trust bought a new position in Bristol-Myers Squibb (NYSE:BMY) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 9,330 shares of the biopharmaceutical company’s stock, valued at approximately $387,000.

A number of other large investors have also recently made changes to their positions in BMY. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the 1st quarter valued at about $27,000. LGT Financial Advisors LLC grew its holdings in Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares during the last quarter. Fairman Group LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at about $42,000. Redmont Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the 1st quarter valued at about $47,000. Finally, Accent Capital Management LLC bought a new position in Bristol-Myers Squibb during the 4th quarter valued at about $46,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Up 1.8 %

NYSE BMY opened at $50.00 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The firm has a market cap of $101.36 billion, a PE ratio of -16.13, a price-to-earnings-growth ratio of 12.59 and a beta of 0.46. The company has a 50 day moving average price of $46.99 and a 200 day moving average price of $46.47. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $59.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.64 by $0.43. The firm had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. Bristol-Myers Squibb’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.75 EPS. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.80%. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Analysts Set New Price Targets

Several research firms have issued reports on BMY. TD Cowen boosted their price objective on shares of Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a research report on Monday, August 12th. Barclays boosted their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a research report on Thursday, August 22nd. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Jefferies Financial Group boosted their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $55.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.